Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 19/20 | 1.00 |
| ▸ | AVPR2 | P30518 | 17/20 | 1.00 |
| ▸ | AVPR1A | P37288 | 15/20 | 1.00 |
| ▸ | AVPR1B | P47901 | 12/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29833233 | 1.00 | OXTR (1.00) | OXTRAVPR2AVPR1AAVPR1B | |
| SCHEMBL12879222 | 0.94 | OXTR (0.89) | OXTRAVPR2AVPR1AAVPR1B | |
| SCHEMBL15576367 | 0.94 | OXTR (0.88) | OXTRAVPR2AVPR1AAVPR1B | |
| SCHEMBL17481277 | 0.91 | OXTR (0.93) | OXTRAVPR2AVPR1AAVPR1B | |
| SCHEMBL18751767 | 0.91 | OXTR (0.83) | OXTRAVPR2AVPR1AAVPR1B | |
| SCHEMBL15576202 | 0.90 | OXTR (0.89) | OXTRAVPR2AVPR1AAVPR1B | |
| SCHEMBL18751768 | 0.88 | OXTR (0.78) | OXTRAVPR2AVPR1AAVPR1B | |
| SCHEMBL15576201 | 0.88 | OXTR (0.78) | OXTRAVPR2AVPR1AAVPR1B | |
| SCHEMBL15576190 | 0.88 | OXTR (0.78) | OXTRAVPR2AVPR1AAVPR1B | |
| SCHEMBL15576204 | 0.87 | OXTR (0.89) | OXTRAVPR2AVPR1AAVPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746850-A1 | EXTENDED RELEASE DRUG-LOADED MICROPARTICLES | Ferring BV (NL) | 2026-05-27 | — | — | EP | claimed |
| US-20250255930-A1 | METHODS OF TREATMENT OF TINNITUS USING DERIVATIVES OF OXYTOCIN | MASKBEGONE LLC (US) | 2025-08-14 | — | — | US | claimed |
| WO-2025017533-A1 | EXTENDED RELEASE DRUG-LOADED MICROPARTICLES | FERRING B.V. (NL) | 2025-01-23 | — | — | WO | claimed |
| EP-4313106-B1 | TREATMENT OF DYSPHAGIA | OT4B (FR) | 2025-01-15 | — | — | EP | claimed |
| US-20240197813-A1 | TREATMENT OF DYSPHAGIA | CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE (FR) | 2024-06-20 | — | — | US | claimed |
| US-20220313774-A1 | INTRANASAL ADMINISTRATION OF MEROTOCIN FOR IMPROVING LACTATION | FERRING B.V. (NL) | 2022-10-06 | — | — | US | claimed |
| WO-2022200568-A1 | TREATMENT OF DYSPHAGIA | OT4B (FR) | 2022-09-29 | — | — | WO | claimed |
| EP-4746850-A1 | EXTENDED RELEASE DRUG-LOADED MICROPARTICLES | Ferring BV (NL) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026106958-A1 | SOFT MIST INHALER AND IMPROVEMENTS THEREFOR | Transpire Bio Inc. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260053883-A1 | OXYTOCIN COMPOSITIONS FOR TREATMENT OF VISUAL SNOW SYNDROME | MASKBEGONE LLC (US) | 2026-02-26 | — | — | US | disclosed |
| US-12485088-B2 | Rapidly-orodispersible tablets having an interior cavity | Aprecia Pharmaceuticals LLC (US) | 2025-12-02 | — | — | US | disclosed |
| US-12466855-B2 | Labeled oxytocin and method of manufacture and use | TONIX PHARMA LIMITED (IE) | 2025-11-11 | — | — | US | disclosed |
| US-20250319153-A1 | MAGNESIUM-CONTAINING OXYTOCIN FORMULATIONS AND METHODS OF USE | TONIX PHARMA LTD (IE) | 2025-10-16 | — | — | US | disclosed |
| US-11389473-B2 | Magnesium-containing oxytocin formulations and methods of use | TONIX PHARMACEUTICALS HOLDING CORP. (US) | 2022-07-19 | — | — | US | disclosed |
| CN-107847552-B | Magnesium-containing oxytocin formulations and methods of use | 三叉神经股份公司 | 2022-07-01 | — | — | CN | disclosed |
| US-20220177512-A1 | CYCLIC PEPTIDE PRODUCTION METHOD | AJINOMOTO CO., INC. (JP) | 2022-06-09 | — | — | US | disclosed |
| WO-2022114955-A1 | SERUM-FREE MEDIUM FOR DIFFERENTIATION OF A PROGENITOR CELL | Mosa Meat B.V. (NL) | 2022-06-02 | — | — | WO | disclosed |
| EP-3981392-A1 | CONTROLLED RELEASE DOSAGE FORM | Triastek, Inc. (CN) | 2022-04-13 | — | — | EP | disclosed |
| US-11278499-B2 | Oral drug dosage form comprising various release profiles | Triastek, Inc. (CN) | 2022-03-22 | — | — | US | disclosed |
| US-20220054409-A1 | RAPIDLY-ORODISPERSIBLE TABLETS HAVING AN INTERIOR CAVITY | Aprecia Pharmaceuticals LLC | 2022-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11278499-B2 | Oral drug dosage form comprising various release profiles | CYP2D6, CYP3A7, CYP3A5 | OXTR 2346/4885AVPR2 1929/4885AVPR1A 2661/4885 |
| US-20240197813-A1 | TREATMENT OF DYSPHAGIA | OXTR, GRPR, NTSR2 | OXTR 1/4885AVPR2 14/4885AVPR1A 22/4885 |
| US-20260053883-A1 | OXYTOCIN COMPOSITIONS FOR TREATMENT OF VISUAL SNOW SYNDROME | OXTR, AVPR2, AVPR1B | OXTR 1/4885AVPR2 2/4885AVPR1A 4/4885 |
| US-20220313774-A1 | INTRANASAL ADMINISTRATION OF MEROTOCIN FOR IMPROVING LACTATION | VIP, VIPR1, OXTR | OXTR 3/4885AVPR2 9/4885AVPR1A 10/4885 |
| US-12466855-B2 | Labeled oxytocin and method of manufacture and use | OXTR, AVPR1A, AVPR1B | OXTR 1/4885AVPR2 6/4885AVPR1A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.